Powered by

DelMar Pharmaceuticals to Host Key Opinion Leader Summit on Glioblastoma Multiforme and the Potential for Treatment with VAL-083; Renowned Experts from Multiple Key GBM Cancer Centers, Including M.D. Anderson Cancer Center and Sun Yat-sen Cancer Center to

Nov 05, 2019 - PR Newswire
Event Announcements

PR Newswire

 DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, today announced it will host a cocktail reception featuring a panel discussion of Delmar's glioblastoma multiforme (GBM) trial status with highly recognized thought leaders in GBM during the 2019 Society for NeuroOncology Annual Meeting in Phoenix, Ariz.

The event will be held on November 22, 2019 at 4:15-5:30 PM MT at...